Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Inflammatory Bowel Diseases

Free Subscription 13.06.2022 3 BMC Gastroenterol 10 Dig Dis Sci 1 Eur J Gastroenterol Hepatol 1 Gastroenterology 2 Gut 24 Inflamm Bowel Dis 2 J Crohns Colitis 4 Lancet 1 PLoS One 4 Z Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Gastroenterol

1. PEYRIN-BIROULET L, Arkkila P, Armuzzi A, Danese S, et al
   Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
   BMC Gastroenterol. 2022;22:291.
   PubMed         Abstract available
   
   
2. LUND K, Larsen MD, Knudsen T, Kjeldsen J, et al
   Physical activity measured by accelerometry in paediatric and young adult patients with inflammatory bowel disease.
   BMC Gastroenterol. 2022;22:290.
   PubMed         Abstract available
   
   
3. XU F, Hu J, Yang Q, Ji Y, et al
   Prevalence and factors associated with fatigue in patients with ulcerative colitis in China: a cross-sectional study.
   BMC Gastroenterol. 2022;22:281.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

4. KUMAR A, Swaminath A
   Impatience with Inpatients: Are Hospitalization Rates Declining for IBD Patients?
   Dig Dis Sci. 2022;67:1927-1929.
   PubMed        
   
   
5. NGUYEN NH, Zhang X, Long MD, Sandborn WJ, et al
   Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases.
   Dig Dis Sci. 2022;67:2039-2048.
   PubMed         Abstract available
   
   
6. GORDON H, Blad W, Trier Moller F, Orchard T, et al
   UK IBD Twin Registry: Concordance and Environmental Risk Factors of Twins with IBD.
   Dig Dis Sci. 2022;67:2444-2450.
   PubMed         Abstract available
   
   
7. ROCCHI C, Soliman YY, Massidda M, Vadala di Prampero SF, et al
   Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review.
   Dig Dis Sci. 2022;67:1948-1955.
   PubMed         Abstract available
   
   
8. SINGH S, Heien HC, Sangaralingham L, Shah ND, et al
   Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-alpha Antagonists in Patients with Inflammatory Bowel Diseases.
   Dig Dis Sci. 2022;67:2510-2516.
   PubMed         Abstract available
   
   
9. SERVAIS L, Boschetti G, Meunier C, Gay C, et al
   Intestinal Conventional Ultrasonography, Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography in Assessment of Crohn's Disease Activity: A Comparison with Surgical Histopathology Analysis.
   Dig Dis Sci. 2022;67:2492-2502.
   PubMed         Abstract available
   
   
10. WATANABE Y, Mizushima T, Okumura R, Fujino S, et al
    Fecal Stream Diversion Changes Intestinal Environment, Modulates Mucosal Barrier, and Attenuates Inflammatory Cells in Crohn's Disease.
    Dig Dis Sci. 2022;67:2143-2157.
    PubMed         Abstract available
    
    
11. COSTABLE NJ, Borman ZA, Ji J, Dubinsky MC, et al
    Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Dig Dis Sci. 2022;67:2480-2484.
    PubMed         Abstract available
    
    
12. XIE M, Xiong Z, Yin S, Xiong J, et al
    Adiponectin Alleviates Intestinal Fibrosis by Enhancing AMP-Activated Protein Kinase Phosphorylation.
    Dig Dis Sci. 2022;67:2232-2243.
    PubMed         Abstract available
    
    
13. VIJAYVARGIYA P, Gonzalez Izundegui D, Calderon G, Tawfic S, et al
    Increased Fecal Bile Acid Excretion in a Significant Subset of Patients with Other Inflammatory Diarrheal Diseases.
    Dig Dis Sci. 2021 Apr 22. pii: 10.1007/s10620-021-06993.
    PubMed         Abstract available
    
    

    
    Eur J Gastroenterol Hepatol

14. GROVA M, Crispino F, Maida M, Macaluso FS, et al
    Authors' reply to 'Use of restrictive iron transfusion strategy in IBD: one size does not fit all'.
    Eur J Gastroenterol Hepatol. 2022;34:808.
    PubMed        
    
    

    
    Gastroenterology

15. ZHU Z, Gao Z, Li K
    Controversy of Preoperative Exposure to Tumor Necrosis Factor Inhibitors in Surgical and Infectious Complications of Inflammatory Bowel Disease.
    Gastroenterology. 2022 Jun 1. pii: S0016-5085(22)00588.
    PubMed        
    
    

    
    Gut

16. WONG ECL, Dulai PS, Narula N
    Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligenc
    Gut. 2022 Jun 7. pii: gutjnl-2022-327661. doi: 10.1136/gutjnl-2022-327661.
    PubMed        
    
    
17. XIONG S, Whitehurst CE, Li L, Heo GS, et al
    Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response.
    Gut. 2022;71:1289-1301.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

18. RANGEL PANIZ G, Lebow J, Sim L, Lacy BE, et al
    Eating Disorders: Diagnosis and Management Considerations for the IBD Practice.
    Inflamm Bowel Dis. 2022;28:936-946.
    PubMed        
    
    
19. ABOUBAKR A, Gottlieb ZS, Riggs AR, Johnson SO, et al
    Peripartum Exposure to Biologic Therapy Does Not Impact Postpartum Wound Healing in Women With IBD.
    Inflamm Bowel Dis. 2022;28:843-849.
    PubMed         Abstract available
    
    
20. BROMS G
    IBD in the Postpartum Period: Spotlight on Maternal Outcomes.
    Inflamm Bowel Dis. 2022;28:980-981.
    PubMed        
    
    
21. WITGES K, Sexton K, Graff LA, Targownik LE, et al
    What Is a Flare? The Manitoba Living With IBD Study.
    Inflamm Bowel Dis. 2022;28:862-869.
    PubMed         Abstract available
    
    
22. NOORIAN S, Jeon Y, Nguyen MT, Sauk J, et al
    The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis.
    Inflamm Bowel Dis. 2022;28:878-887.
    PubMed         Abstract available
    
    
23. JAVAID A, Shahab O, Adorno W, Fernandes P, et al
    Machine Learning Predictive Outcomes Modeling in Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2022;28:819-829.
    PubMed         Abstract available
    
    
24. CHEN G, Pedarla V, Null KD, Cazzetta SE, et al
    Health Care Costs and Resource Utilization Among Patients With Crohn's Disease With and Without Perianal Fistula.
    Inflamm Bowel Dis. 2022;28:870-877.
    PubMed         Abstract available
    
    
25. FRADKOV E, Sheehan J, Cushing K, Higgins PDR, et al
    Efficacy of Ustekinumab in Crohn's Disease With and Without Concurrent Autoimmune Skin Disease.
    Inflamm Bowel Dis. 2022;28:895-904.
    PubMed         Abstract available
    
    
26. SORENSEN KM, Jensen CH, Sheikh SP, Qvist N, et al
    Treatment of Fistulizing Perianal Crohn's Disease by Autologous Microfat Enriched With Adipose-Derived Regenerative Cells.
    Inflamm Bowel Dis. 2022;28:967-970.
    PubMed        
    
    
27. BAI X, Zhang H, Ruan G, Lv H, et al
    Long-term Disease Behavior and Surgical Intervention Analysis in Hospitalized Patients With Crohn's Disease in China: A Retrospective Cohort Study.
    Inflamm Bowel Dis. 2022;28.
    PubMed         Abstract available
    
    
28. WANG X, Tang J, Zheng JW, Huang WF, et al
    Granulomatous Pneumonia and Liver Lesions Associated With Crohn's Disease.
    Inflamm Bowel Dis. 2022;28:e78-e79.
    PubMed        
    
    
29. DONG G, Yang Y, Zhang H, Yu W, et al
    Protein Kinase CK2 Maintains Reciprocal Balance Between Th17 and Treg Cells in the Pathogenesis of UC.
    Inflamm Bowel Dis. 2022;28:830-842.
    PubMed         Abstract available
    
    
30. TIAN WN, Huang YH, Dai C
    Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: A Survey From China.
    Inflamm Bowel Dis. 2022 Jun 6. pii: 6603234. doi: 10.1093.
    PubMed        
    
    
31. JEDEL S, Beck T, Swanson G, Hood MM, et al
    Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial.
    Inflamm Bowel Dis. 2022 Jun 4. pii: 6602039. doi: 10.1093.
    PubMed         Abstract available
    
    
32. TURSI A, Nenna R
    COVID-19 as a Trigger for De Novo Crohn's Disease.
    Inflamm Bowel Dis. 2022;28:e76-e77.
    PubMed        
    
    
33. ZHANG Y, Tian F, Li H
    Pulmonary Infection Due to Reactivation of Latent Epstein-Barr Virus in a Patient With Crohn's Disease Treated With Infliximab.
    Inflamm Bowel Dis. 2022;28:e80-e81.
    PubMed        
    
    
34. STIDHAM RW, Yu D, Zhao X, Bishu S, et al
    Identifying the Presence, Activity, and Status of Extraintestinal Manifestations of Inflammatory Bowel Disease Using Natural Language Processing of Clinical Notes.
    Inflamm Bowel Dis. 2022 Jun 3. pii: 6601382. doi: 10.1093.
    PubMed         Abstract available
    
    
35. CAO Q, Chen C, Gao X, Chen Y, et al
    Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China.
    Inflamm Bowel Dis. 2022;28.
    PubMed        
    
    
36. YU M, Zhu W, Wang J, Chen X, et al
    Caveolin-1 Alleviates Crohn's Disease-induced Intestinal Fibrosis by Inhibiting Fibroblasts Autophagy Through Modulating Sequestosome 1.
    Inflamm Bowel Dis. 2022;28:923-935.
    PubMed         Abstract available
    
    
37. PENG L, Hu S, Yu Q, Chen Y, et al
    Challenging the Surge of Inflammatory Bowel Disease: The Role of the China Crohn's and Colitis Foundation in the Healthcare Landscape of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2022;28.
    PubMed         Abstract available
    
    
38. CHEN YJ, Chen BL, Liang MJ, Chen SL, et al
    Longitudinal Bowel Behavior Assessed by Bowel Ultrasound to Predict Early Response to Anti-TNF Therapy in Patients With Crohn's Disease: A Pilot Study.
    Inflamm Bowel Dis. 2022;28.
    PubMed         Abstract available
    
    
39. WANG B, Li R, Zhang S, Zhao Q, et al
    A Case of Behcet's Disease With Hepatic Lesions Misdiagnosed as Crohn's Disease.
    Inflamm Bowel Dis. 2022;28:e86-e87.
    PubMed        
    
    
40. ARKENBOSCH JHC, Mak JWY, Ho JCL, Beelen EMJ, et al
    Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West.
    Inflamm Bowel Dis. 2022;28.
    PubMed         Abstract available
    
    
41. YAO L, Chen H, Shao B, Liu J, et al
    Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China.
    Inflamm Bowel Dis. 2022;28.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

42. CLARKSTON K, Karns R, Jegga AG, Sharma M, et al
    Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis.
    J Crohns Colitis. 2022 Jun 4. pii: 6602063. doi: 10.1093.
    PubMed         Abstract available
    
    
43. JAGT JZ, Verburgt CM, de Vries R, de Boer NKH, et al
    Faecal metabolomics in paediatric inflammatory bowel disease: a systematic review.
    J Crohns Colitis. 2022 Jun 9. pii: 6605030. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Lancet

44. D'HAENS G, Panaccione R, Baert F, Bossuyt P, et al
    Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
    Lancet. 2022;399:2015-2030.
    PubMed         Abstract available
    
    
45. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.
    PubMed        
    
    
46. FERRANTE M, Panaccione R, Baert F, Bossuyt P, et al
    Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
    Lancet. 2022;399:2031-2046.
    PubMed         Abstract available
    
    
47. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Sweet's syndrome and Crohn's disease diagnosed simultaneously.
    Lancet. 2022;399:2155.
    PubMed        
    
    

    
    PLoS One

48. WEDENOJA S, Saarikivi A, Malkonen J, Leskinen S, et al
    Fecal microbiota in congenital chloride diarrhea and inflammatory bowel disease.
    PLoS One. 2022;17:e0269561.
    PubMed         Abstract available
    
    

    
    Z Gastroenterol

49. MENZE L, Wenzl TG, Pappa A
    [KARLOTTA (Kids + Adolescents Research Learning On Tablet Teaching Aachen) - randomized controlled pilot study for the implementation of a digital educational app with game of skill for pediatric patients with inflammatory bowel disease].
    Z Gastroenterol. 2022 Jun 7. doi: 10.1055/a-1799-9267.
    PubMed         Abstract available
    
    
50. HAZIRI D, Stallmach A
    
    Z Gastroenterol. 2022;60:1038-1039.
    PubMed        
    
    
51. KUCHARZIK T, Atreya R, Bachmann O, Baumgart DC, et al
    [Position paper on reporting of intestinal ultrasound findings in patients with inflammatory bowel disease].
    Z Gastroenterol. 2022;60:978-990.
    PubMed         Abstract available
    
    
52. IESALNIEKS I, Agha A, Dederichs F, Schlitt HJ, et al
    [Bowel resections for Crohn's disease: developments over the last three decades].
    Z Gastroenterol. 2022;60:927-936.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: